

**HD** Trading in Nexstim Plc's shares commences today on Nasdaq First North Finland and Nasdaq First North Sweden

**WC** 1,236 words

**PD** 14 November 2014

**ET** 18:30

**SN** Thomson Reuters ONE

**SC** HUGNEN

**LA** English

**CY** © 2014 All Rights Reserved. Thomson Reuters.

**LP**

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE USA, AUSTRALIA, CANADA, **HONG KONG**, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL.

Trading in Nexstim Plc's shares commences today on Nasdaq First North Finland and Nasdaq First North Sweden

**TD**

Helsinki, 14 November 2014 at 9:30 am

Nexstim Plc ("Nexstim" or the "**Company**"), a medical technology **company** aiming to improve rehabilitation for stroke patients through the use of non-invasive brain stimulation, announces its flotation today on Nasdaq's First North market in Helsinki (NXTMH) and Stockholm (NXTMS).

"Our listing today on First North in Helsinki and Stockholm is a significant step in the growth of Nexstim and shows the quality and enthusiasm for our medical technology for navigated brain stimulation", commented Nexstim's CEO, Janne Huhtala.

Nexstim has raised gross proceeds of EUR 15.3 **million** with a total of 2,408,339 new shares issued in the initial public offering (the "Offering"). The new shares were registered with the Finnish Trade Register on 13 November 2014. The **Company**'s previous major shareholders, HealthCap, the Finnish Innovation Fund Sitra, Capricorn Health-Tech Fund, Life Sciences Partners (LSP) and Lundbeckfond Ventures have all increased their holdings and they have been joined by international institutional investors and retail investors in Finland and Sweden.

The proceeds of the Offering will be used to finance Nexstim through the **Company**'s next development stage through to the end of the Phase III multi-centre trial and FDA clearance for marketing its NBT System in stroke therapy, expected to take place at the end of 2016.

"We are delighted to welcome our new investors and would like to thank them, and existing shareholders, for their support. We look forward to updating the market on our Phase III multi-centre trial for NBT in stroke rehabilitation, which continues to progress according to plan, and on the progress of our newly launched NBS 5 System, our next generation device for pre-surgical mapping in neurosurgery", says Janne Huhtala.

In the Offering, Pareto Securities AB acted as **Lead** Financial Advisor and Joint Arranger and UB Securities Ltd acted as Financial Co-Advisor and Joint Arranger. The **Company**'s Certified Adviser under the First North rules is UB Capital Ltd. Krogerus Attorneys Ltd and Advokatfirman Vinge KB acted as legal advisors to the **Company** in the Offering.

Additional information on the Offering is available in the prospectus published by Nexstim on 13 October 2014, supplemented on 30 October 2014, available at [www.nexstim.com/IPO](http://www.nexstim.com/IPO).

For further information please visit [www.nexstim.com](http://www.nexstim.com) or contact:

Nexstim  
+358 40 8615046

Janne Huhtala, Chief Executive Officer

[janne.huhtala@nexstim.com](mailto:janne.huhtala@nexstim.com)

UB Capital Ltd  
(9) 2538 0225

+358

Consilium Strategic Communications  
5700

+44 (0)20 3709

Mary-Jane Elliot  
[nexstim@consilium-comms.com](mailto:nexstim@consilium-comms.com)

Amber Bielecka

Ivar Milligan

Laura Thornton

About Nexstim

Nexstim, formed in 2000 and based in Finland, is a medical technology **company** aiming to improve rehabilitation for stroke patients. Nexstim has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) device for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the **company** has developed a device for stroke therapy called Navigated Brain Therapy (NBT®). In H1 2014, Nexstim initiated a two-year pivotal Phase III study at 12 sites in the US aiming to demonstrate the effectiveness of NBT® and gain FDA clearance for commercialisation in post-acute stroke therapy in the US. For more information please visit [www.nexstim.com](http://www.nexstim.com).

#### IMPORTANT NOTICE

This announcement is not a prospectus. The information contained herein does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any **sale** of the securities referred to herein, in any jurisdiction in which such offer, solicitation or **sale** would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction. The Offering is made solely on the basis of the prospectus approved by the Finnish Financial Supervisory Authority on 10 October 2014, as supplemented on 30 October 2014, and passported by way of notification to the Swedish Financial Supervisory Authority.

This communication is not addressed to the public in any Member State of the European Economic Area other than Finland and Sweden. With respect to each Member State of the European Economic Area other than Finland and Sweden (each, a "Relevant Member State"), no action has been undertaken to date to make an offer to the public of the securities requiring a publication of a prospectus in any Relevant Member State. As a result, this communication is only addressed to and directed at qualified investor in the Relevant Member States in circumstances not requiring the **Company** to publish a prospectus for the purposes of Directive 2003/71/EC (together with any applicable implementing measures in any Member State).

This announcement is not an offer for **sale** nor a solicitation of an offer to buy any securities in the United States or outside the European Economic Area. The securities referred to in this announcement may not be offered or sold in or into the United States of America absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Nexstim has not registered and will not register any part of its contemplated offering in the United States nor will it offer any securities to the public in the United States.

This communication is only being distributed to and is directed only at (i) persons who are outside the United Kingdom, or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order, and (iv) other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons"). Any investment or investment activity to which this communication relates will only be available to and will only be engaged in with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

Securities in the **Company** have not been, and will not be, registered under the applicable securities laws of Australia, Canada, **Hong Kong**, Japan or South Africa and may not be offered or sold within Australia, Canada, Japan or South Africa or to, or for the account or benefit of, citizens or residents of Australia, Canada, **Hong Kong**, Japan or South Africa except under circumstances which will result in full compliance with the applicable laws and regulations promulgated by the relevant regulatory authorities in effect at the relevant time.

[Nexstim press release](#)

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Nexstim Oyj via Globenewswire

HUG#1871307

**CT**

**CO** nexsto : Nexstim Oy

**IN** itheradv : Therapeutic Devices/Equipment | i372 : Medical Equipment/Supplies | i951 : Health Care/Life Sciences | iphmed : Medical/Surgical Instruments/Apparatus/Devices

**NS** npress : Press Releases | ncat : Content Types

**RE** fin : Finland | swed : Sweden | austr : Australia | helsnk : Helsinki | hkong : Hong Kong | jap : Japan | safr : South Africa | usa : United States | africaz : Africa | apacz : Asia Pacific | asiaz : Asia | ausnz : Australia/Oceania | bric : BRICS Countries | china : China | chinaz : Greater China | devgcoz : Emerging Market Countries | dvpcoz : Developing Economies | easiaz : Eastern Asia | eecz : European Union Countries | eurz : Europe | namz : North America | nordz : Nordic Countries | scandz : Scandinavia | souafrz : Southern Africa

**IPD** Healthcare

**PUB** Thomson Reuters (Markets) Norway AS

**AN** Document HUGNEN0020141114eabe000ji